Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study
Autoři:
Leora R. Feldstein aff001; Sarah D. Bennett aff002; Concepcion F. Estivariz aff002; Gretchen M. Cooley aff003; Lauren Weil aff004; Mallick Masum Billah aff005; M. Salim Uzzaman aff005; Rajendra Bohara aff006; Maya Vandenent aff007; Jucy Merina Adhikari aff007; Eva Leidman aff008; Mainul Hasan aff007; Saifuddin Akhtar aff007; Andreas Hasman aff009; Laura Conklin aff002; Daniel Ehlman aff002; A. Alamgir aff005; Meerjady Sabrina Flora aff005
Působiště autorů:
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff001; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff002; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff003; Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff004; Institute of Epidemiology, Disease Control and Research, Dhaka, Bangladesh
aff005; World Health Organization, Dhaka, Bangladesh
aff006; United Nations Children’s Fund, Dhaka, Bangladesh
aff007; Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff008; United Nations Children’s Fund, Regional Office for South Asia, Kathmandu, Nepal
aff009
Vyšlo v časopise:
Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study. PLoS Med 17(3): e32767. doi:10.1371/journal.pmed.1003071
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1003071
Souhrn
Background
During August 2017–January 2018, more than 700,000 forcibly displaced Rohingyas crossed into Cox’s Bazar, Bangladesh. In response to measles and diphtheria cases, first documented in September and November 2017, respectively, vaccination campaigns targeting children <15 years old were mobilized during September 2017–March 2018. However, in a rapidly evolving emergency situation, poor sanitation, malnutrition, overcrowding, and lack of access to safe water and healthcare can increase susceptibility to infectious diseases, particularly among children. We aimed to estimate population immunity to vaccine-preventable diseases (VPDs) after vaccination activities in the camps to identify any remaining immunity gaps among Rohingya children.
Methods and findings
We conducted a cross-sectional serologic and vaccination coverage survey in Nayapara Registered Refugee Camp (“Nayapara”) and makeshift settlements (MSs) April 28, 2018 to May 31, 2018, among 930 children aged 6 months to 14 years. MSs are informal, self-settled areas with a population of more than 850,000, the majority of whom arrived after August 2017, whereas Nayapara is a registered camp and has better infrastructure than MSs, including provision of routine immunization services. Households were identified using simple random sampling (SRS) in Nayapara and multistage cluster sampling in MSs (because household lists were unavailable). Dried blood spots (DBSs) were collected to estimate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex multiplex bead assay (MBA). Caregiver interviews assessed vaccination campaign participation using vaccination card or recall. In Nayapara, 273 children aged 1 to 6 years participated; 46% were female and 88% were registered refugees. In MSs, 358 children aged 1 to 6 years and 299 children aged 7 to 14 years participated; 48% of all children in MSs were female, and none were registered refugees. In Nayapara, estimated seroprotection among 1- to 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%–98%; 95% confidence interval [CI] 87%–99%); children >6 years were not assessed. In MSs, measles seroprotection was similarly high among 1- to 6-year-olds and 7- to 14-year-olds (91% [95% CI 86%–94%] and 99% [95% CI 96%–100%], respectively, p < 0.001). Rubella and diphtheria seroprotection in MSs were significantly lower among 1- to 6-year-olds (84% [95% CI 79%–88%] and 63% [95% CI 56%–70%]) compared to 7- to 14-year-olds (96% [95% CI 90%–98%] and 77% [95% CI 69%–84%]) (p < 0.001). Tetanus seroprevalence was similar among 1- to 6-year-olds and 7- to 14-year-olds (76% [95% CI 69%–81%] and 84% [95% CI 77%–89%], respectively; p = 0.07). Vaccination campaign coverage was consistent with seroprotection in both camps. However, nonresponse, the main limitation of the study, may have biased the seroprotection and campaign coverage results.
Conclusions
In this study, we observed that despite multiple vaccination campaigns, immunity gaps exist among children in MSs, particularly for diphtheria, which requires serial vaccinations to achieve maximum protection. Therefore, an additional tetanus-diphtheria campaign may be warranted in MSs to address these remaining immunity gaps. Rapid scale-up and strengthening of routine immunization services to reach children and to deliver missed doses to older children is also critically needed to close immunity gaps and prevent future outbreaks.
Klíčová slova:
Bangladesh – Cholera vaccines – Immunity – Measles – Serology – Vaccination and immunization – Diphtheria – Tetanus
Zdroje
1. Inter Sector Coordination Group. Situation Report: Rohingya Refugee Crisis Cox's Bazar: Inter Sector Coordination Group; 2018 [updated January 27, 2018]. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/180127_weekly_iscg_sitrep_final.pdf. [cited 2019 Apr 20].
2. Practical Action Publishing. The Sphere Project. Sphere project humanitarian charter and minimum standards of disaster response. United Kingdom: Practical Action Publishing, 2011.
3. World Health Organization. Situation Report: Arrival of Rohingya population from Myanmar following conflict in Rahkine state. Cox's Bazar, Bangladesh: World Health Organization, 2017.
4. World Health Organization. Mortality and Morbidity Weekly Bulletin 2017;9.
5. World Health Organization. The Immunological Basis For Immunization Series, Module 7: Measles. Geneva: World Health Organization, 2009.
6. World Health Organization. The Immunological Basis For Immunization Series, Module 2: Diphtheria. Geneva: World Health Organization, 2009.
7. World Health Organization. Bangladesh: Rohingya Emergency Reponse Early Warning, Alert and Response System (EWARS) Epidemiologcal Bulletin W32 2018.
8. Jalloh MF, Bennett SD, Alam D, Kouta P, Lourenco D, Alamgir M, et al. Rapid behavioral assessment of barriers and opportunities to improve vaccination coverage among displaced Rohingyas in Bangladesh, January 2018. Vaccine. 2019;37(6):833–8. Epub 2019/01/16. doi: 10.1016/j.vaccine.2018.12.042 30642728
9. International Organization for Migration. IOM Bangladesh—Needs and Population Monitoring (NPM) Round 12 Site Assessment 2018. Available from: https://data.humdata.org/dataset/iom-bangladesh-needs-and-population-monitoring-npm-round-12-site-assessment. [cited 2019 Apr 20].
10. Inter Sector Coordination Group. Situation Report Rohingya Refugee Crisis Cox's Bazar, Bangladesh: Inter Sector Coordination Group; 2018 [updated July 19 2018]. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/iscg_situation_report_19_july_2018.pdf.
11. Action Against Hunger Canada. Standardized Monitoring and Assessment for Relief and Transitions Methodology Manual 2.0. Action Against Hunger Canada, 2017.
12. STATA Survey Data Reference Manual, College Station, Texas: Stata Press; 2013 [January 2016, 2020]. Available from: https://www.stata.com/manuals13/svy.pdf. [cited 2019 Apr 25].
13. Mahmood SS, Wroe E, Fuller A, Leaning J. The Rohingya people of Myanmar: health, human rights, and identity. Lancet. 2017;389(10081):1841–50. Epub 2016/12/06. doi: 10.1016/S0140-6736(16)00646-2 27916235.
14. The Republic of the Union of Myanmar Ministry of Health. Expanded Programme on Immunization, Myanmar Multi Year Plan 2012–2016 Ministry of Health, The Republic of the Union of Myanmar, 2016.
15. Kheir AE, Alhaj AA, Ibrahim SA. The sensitivity of BCG scar as an indicator of previous vaccination among Sudanese infants. Vaccine. 2011;29(46):8189–91. Epub 2011/09/07. doi: 10.1016/j.vaccine.2011.08.095 21893144.
16. Expanded programme on immunization. Programme review. Wkly Epidemiol Rec. 1994;69(12):87–90. Epub 1994/03/25. 8003403.
17. World Health Organization. Diphtheria vaccine: WHO position paper. Geneva: World Health Organization 2017 Contract No.: 31.
18. World Health Organization. The Immunological Basis for Immunization Series, Module 3: Tetanus. Geneva: World Health Organization, 2018.
19. World Health Organization. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. Geneva: World Health Organization, 2013.
20. Scobie HM, Mao B, Buth S, Wannemuehler KA, Sorensen C, Kannarath C, et al. Tetanus Immunity among Women Aged 15 to 39 Years in Cambodia: a National Population-Based Serosurvey, 2012. Clin Vaccine Immunol. 2016;23(7):546–54. Epub 2016/04/08. doi: 10.1128/CVI.00052-16 27053629; PubMed Central PMCID: PMC4933773.
21. World Health Organization. Vaccination in Acute Humanitarian Emergences: a Framework for Decision-Making. Geneva, Switzerland: 2013.
Článek vyšel v časopise
PLOS Medicine
2020 Číslo 3
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Proč při poslechu některé muziky prostě musíme tančit?
- Chůze do schodů pomáhá prodloužit život a vyhnout se srdečním chorobám
- „Jednohubky“ z klinického výzkumu – 2024/44
- Je libo čepici místo mozkového implantátu?
Nejčtenější v tomto čísle
- Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses
- An Integrative Adapt Therapy for common mental health symptoms and adaptive stress amongst Rohingya, Chin, and Kachin refugees living in Malaysia: A randomized controlled trial
- Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial
- Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial